Report Code: A13202 | Pages: NA | ||
Tables: NA | Charts: NA |
|
Impetigo Treatment Market Outlook 2030
Impetigo is very common and contagious skin infection disease that generally affects infants and children. This type of infection is caused due to streptococcus or staphylococcus aureus bacteria. Patient who suffer from this infection shows red scores or bump blisters on their faces particularly around their nose, feet, hands, and mouth. This disease is rarely found in adults. People which are in sports activities involving close physical contacts such as wrestling and rugby are susceptible to this disease. Impetigo can be treated with oral drugs such as cephalosporins, penicillin, and tertracycline. Moreover, topical creams help to reduce symptoms of this disease.
COVID-19 Impact Analysis
COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the impetigo treatment market.
Top Impacting Factors
Market Trends
New Product Launches to Flourish the Market
In 2018, Cutanea Life Sciences announced launch of Xepi Cream, 1%. Xepi cream is a non-fluorinated topical quinolone used in treatment of impetigo in adult and pediatric patients.
In 2018, Medimetriks Pharmaceutical announced launch of novel topical Ozenoxacin cream. This cream recent got approval from Food and Drug Administration and can be used in treatment of impetigo.
Key Benefits of the Report
Questions Answered in the Impetigo Treatment Market Report
Impetigo Treatment Market Report Highlights
Aspects | Details |
---|---|
By Drug Class |
|
By Route of Administration |
|
By Distribution Channel |
|
By Region |
|
Key Market Players | Pfizer, Inc., Roche Holding AG, Teva Pharmaceutical Industries Ltd, GlaxoSmithKline plc, Karalex Pharma, LLC, SANDOZ GmbH, Ranbaxy Laboratories Limited, Lupin Limited, NovaBay Pharmaceuticals, Inc., Taro Pharmaceutical Industries Ltd, Leo Pharma A/S |
Loading Table Of Content...
Start reading.
This Report and over 71,223+ more Reports, Available with Avenue Library. T&C*.
10%
Discount
10%
Discount
15%
Discount
15%
Discount
Enterprise
License/PDF
20%
Discount
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of the scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time for readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of the scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save the time of readers